OBJECTIVE: To evaluate the correlation between mean superior thyroid artery peak systolic velocity (STA-PSV) and radioactive iodine uptake (RAIU) in Chinese patients with untreated thyrotoxicosis, using retrospectively and prospectively collected data. METHODS: Patients with untreated thyrotoxicosis (n = 220) and euthyroid control subjects (n = 30) underwent thyroid function, thyroid autoantibody and thyroid ultrasonography tests. Mean STA-PSV was measured by ultrasonography. RAIU tests identified 168 patients with Graves' disease and 52 with destructive thyroiditis. Linear correlation of mean STA-PSV with 3-h and 24-h RAIU, and sensitivity, specificity and receiver operating characteristic (ROC) curves for mean STA-PSV in the differential diagnosis of Graves' disease and destructive thyroiditis were calculated. RESULTS: Mean STA-PSV was significantly higher in Graves' disease than in destructive thyroiditis. Mean STA-PSV correlated positively and significantly with 3-h and 24-h RAIU. Area under the ROC curve of mean STA-PSV for the differential diagnosis of Graves' disease and destructive thyroiditis was 0.825 (optimum cut-off value of mean STA-PSV, 45.25 cm/s; sensitivity, 80.4%; specificity, 81.4%). CONCLUSIONS: Detection of mean STA-PSV by ultrasonography agrees with RAIU and is useful for the differential diagnosis of thyrotoxicosis in Chinese patients.
Introduction
Thyrotoxicosis refers to the classic physiological manifestations of excessive quantities of thyroid hormones. The term hyperthyroidism is reserved for describing disorders that result from sustained overproduction of hormone by the thyroid itself, Graves' disease being the most common. Graves' disease can be treated with antithyroid drugs, radioisotope therapy or subtotal thyroidectomy, whereas destructive thyroiditis is often managed conservatively. 1 If destructive thyroiditis is misdiagnosed as Graves' disease and treated with antithyroid L Chen, X Zhao, H Liu et al. Mean STA-PSV in thyrotoxicosis drugs then hypothyroidism, drug-induced hepatitis or leucopenia may occur. 2, 3 Correct and prompt diagnosis is therefore important in order to ensure appropriate treatment selection. Improvements in diagnostic technology have allowed early diagnosis of Graves' disease, even without its typical manifestations such as exophthalmos, pretibial myxoedema or goitre. 4 Several tests, including radioactive iodine uptake (RAIU), technetium thyroid scan, ratio of serum tri-iodothyronine to thyroxine, 5 serum total alkaline phosphatase activity 6 and serum antithyrotropin receptor antibody (TRAb) 7 have been used for the differential diagnosis of transient thyrotoxicosis and Graves' disease. These tests are not generally available in hospitals and clinics in China, and it can take several days to obtain the results. RAIU is recognized as the most accurate test, 1 but the ingestion of iodine-containing foods or drugs can interfere with the results, requiring patients to maintain low-iodine diets for 2 weeks before being tested. In addition, RAIU is contraindicated during pregnancy and lactation 8 and, if this test is used to evaluate amiodarone-induced thyrotoxicosis, the patient has first to discontinue medication. 9 Ultrasonography with pulsed Doppler equipment is a noninvasive and cost-effective method for rapidly obtaining useful information. High intrathyroidal blood flow and an increase in mean peak systolic velocity (PSV) of the thyroid artery are wellknown signs of Graves' disease. 10 Thyroid vascularity can be used to predict the longterm course of Graves' disease while on medical therapy, 11 and disease outcome after withdrawal of antithyroid drugs. 10 Colour flow Doppler (CFD) ultrasonography can accurately differentiate between type 1 and type 2 amiodarone-induced thyrotoxicosis, and the results are generally in agreement with RAIU findings. 9 Examination of CFD ultrasonography patterns is subjective, however, and it is difficult to quantify the findings. PSV of the superior thyroid artery (STA-PSV) is more sensitive in the differential diagnosis of thyrotoxicosis compared with CFD ultrasonography pattern determination, since the former is quantitative and the latter is qualitative. 12 The consistency between thyroid PSV and RAIU findings has not been verified. The present study evaluated the correlation between STA-PSV and RAIU in Chinese patients with thyrotoxicosis.
Patients and methods

STUDY POPULATIONS
Retrospective study A retrospective study was conducted using thyrotoxicosis clinical data collected at Huashan Hospital, Fudan University, Shanghai, China, between February 2006 and June 2009. Data from patients with newly diagnosed thyrotoxicosis were analysed. All participants had undergone concurrent RAIU, STA-PSV and thyroid function analyses. Thyroid ultrasonography was used to exclude patients with autonomous adenoma and multiple nodules. RAIU was set as the gold standard to differentiate between Graves' disease and destructive thyroiditis.
Thyrotoxicosis was defined as elevated serum free tri-iodothyronine (FT 3 > 6.5 pmol/l), elevated serum free thyroxine (FT 4 > 31.0 pmol/l) and suppressed thyroid stimulating hormone (TSH < 0.350 mIU/l) concentrations. Patients with thyrotoxicosis, elevated RAIU (3 h ≥ 10% and/or 24 h ≥ 45%) and/or typical manifestations such as diffuse goitre, exophthalmos, pretibial myxoedema and elevated TRAb concentrations (> 5 IU/l) were defined as having Graves' disease. The remaining patients with thyrotoxicosis and suppressed RAIU (3 h < 10% and 24 h < 45%) L Chen, X Zhao, H Liu et al.
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were diagnosed as having destructive thyroiditis.
Prospective study
A prospective study was subsequently conducted (ClinicalTrials.gov identifier: NCT01227499). Patients with thyrotoxicosis were consecutively recruited from Huashan Hospital, Fudan University, Shanghai, China and Zhongda Hospital of Southeast University, Nanjing, China, between July 2009 and November 2010. Patients with newly diagnosed thyrotoxicosis without antithyroid intervention, including antithyroid drugs and β-blockers, were included in the study. The definitions of Graves' disease and destructive thyroiditis were the same as those used for the retrospective analysis. If the diagnosis was inconsistent with the clinical manifestations and difficult to confirm, patients were followed up for 3 months. All patients with thyrotoxicosis underwent RAIU and STA-PSV tests. Control subjects without thyroid disease were recruited from subjects attending Huashan Hospital for routine physical examinations.
Exclusion criteria for the retrospective and prospective studies were: (i) multinodular goitre; (ii) toxic nodular goitre; (iii) history of thyroid surgery; (iv) radioactive iodide treatment or neck irradiation; (v) medication such as antithyroid drugs or thyroxine pills in the previous 2 -4 weeks; (vi) a high-iodine diet (e.g. including foods such as sea tangle and laver) in the previous 2 -4 weeks; (vii) iodine-containing medication such as contrast medium and amiodarone; and (viii) pregnancy or lactation.
The Ethics Committees of Huashan Hospital (reference number HIRB 2010-111) and Zhongda Hospital of Southeast University (reference number ZIRB 2010-089) approved the study protocol. All participants provided written informed consent.
MEASUREMENT OF SEROLOGICAL MARKERS
Blood was sampled from all study participants into tubes containing heparin (0.5 mg/ml), and stored at -20°C prior to analysis. Serum FT 4 , FT 3 and TSH concentrations were measured using electrochemiluminescence immunoassay (Elecsys ® E170, Roche Diagnostics, Tokyo, Japan), with an intra-assay coefficient of variation (CV) of 3.9% and an interassay CV of 8.9%. TRAb was measured using enzymelinked immunosorbent assay (ElisaRSR™ TRAb 3rd generation kit; RSR, Cardiff, UK), with an intra-assay CV of 4.2% and an interassay CV of 9.1%. Thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) were measured using radioimmunoassay (RiaRSR™ TPOAb, RiaRSR™ TgAb; both from RSR), with an intra-assay CV of 4.2% and an interassay CV of 6.8%. Normal values were as follows: FT 4 , 10.2 -31.0 pmol/l; FT 3 , 3.5 -6.5 pmol/l; TSH, 0.350 -5.500 mIU/l; TgAb, 0 mIU/ml; TPOAb, 0 mIU/ml; and TRAb, < 5 IU/l.
CFD ULTRASONOGRAPHY
Ultrasound examinations were performed independently by two experts, using a GE LOGIQ ® 9 colour Doppler imaging system (GE Healthcare Biosciences, Piscataway, NJ, USA). Both operators examined all patients and any disputed results were resolved via discussion. The LOGIQ ® 9 system processes the signal from a 7.5 MHz linear phased array transducer to a real-time grey-scale image with coloured areas, representing moving blood cells. In addition, the real-time Doppler shift (i.e. frequency shift; ∆f ) at any point on the screen can be sampled with the samplevolume cursor. The angle (α) between the ultrasound beam and the vessel is selected on the screen with the angle cursor, and the flow velocity envelope curve is displayed on the L Chen, X Zhao, H Liu et al. Mean STA-PSV in thyrotoxicosis monitor. PSV can be calculated for any selected portion of this curve.
The STA arises from the external carotid artery, just below the level of the greater cornu of the hyoid bone, and ends in the thyroid gland. After the participant had rested for 10 min, the left STA was identified and the sample-volume cursor was positioned within the axis of a straight stretch of the vessel. The spectral waveform was stored digitally, and this procedure was repeated for the right STA and carotid artery. All registrations were stored anonymously, using a preassigned code number. Three measurements were performed and the mean STA-PSV was defined as the mean PSV for the left and right STA.
RADIOACTIVE IODINE UPTAKE
Thyroid RAIU was determined 3 h and 24 h after administration of 0.5 MBq (14 µCi) 131 I by mouth, using a collimated 5.08 cm 2 thallium-doped sodium iodide scintillation probe (Atomlab™ 950; Biodex Medical Systems, Shirley, NY, USA) with dead-time correction. The probe was calibrated by placing the 131 I tracer dose in a neck phantom (Thyroid Uptake Neck Phantom; Biodex Medical Systems, Shirley, NY, USA) and the counting rate was measured at a fixed distance (30 cm from the detector).
STATISTICAL ANALYSES
Normally distributed data were expressed as mean ± SD. Variables with a skewed distribution were reported as median (interquartile range) and log transformed to approximate normality before analysis. The Student's t-test or the Mann-Whitney U-test were used to compare differences between groups. The linear correlations of mean STA-PSV with 3-h and 24-h RAIU were calculated. Receiver operating characteristic (ROC) curves, sensitivity and specificity for mean STA-PSV in the differential diagnosis of Graves' disease and destructive thyroiditis were calculated. Statistical analyses were carried out using SPSS ® software, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value < 0.05 was considered to be statistically significant.
Results
The retrospective part of the study included data for 135 patients with newly diagnosed thyrotoxicosis. The prospective part of the study included 85 patients diagnosed with thyrotoxicosis and 30 control subjects without thyroid disease. A total of 168 patients with Graves' disease and 52 patients with destructive thyroiditis were included in the data analyses.
Demographic and clinical characteristics, and results of thyroid tests undertaken in the study participants, are given in Table 1 . Patients with Graves' disease had significantly higher STA-PSV and FT 3 , FT 4 , TRAb, TPOAb, TgAb and 3-h and 24-h RAIU levels, compared with those who had destructive thyroiditis (P < 0.05, all comparisons). TSH levels were significantly higher in patients with destructive thyroiditis compared with patients with Graves' disease (P < 0.05). Mean STA-PSV was significantly lower in control subjects than in patients with Graves' disease (P < 0.05). FT 3 and FT 4 levels were significantly higher, and TSH levels were significantly lower, in patients with Graves' disease or destructive thyroiditis compared with control subjects (P < 0.05, all comparisons).
In the patients with thyrotoxicosis (n = 220), mean STA-PSV correlated positively and significantly with 3-h RAIU (r = 0.532, P < 0.001; Fig. 1A ) and 24-h RAIU findings (r = 0.471, P < 0.001; Fig. 1B) .
The area under the ROC curve of mean STA-PSV for the differential diagnosis of L Chen, X Zhao, H Liu et al.
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Graves' disease and destructive thyroiditis was 0.825 ( Fig. 2A) . The optimum cut-off value of mean STA-PSV was 45.25 cm/s, with a sensitivity of 80.4% and specificity of 81.4%. The area under the ROC curve of the FT 3 /FT 4 ratio for the differential diagnosis of Graves' disease and destructive thyroiditis was 0.527 ( Fig. 2B ).
Discussion
As a marker of thyroid function, PSV has been shown to predict methimazole sensitivity in untreated Graves' disease, 13 and disease relapse after antithyroid drug withdrawal. 14, 15 STA-PSV is useful in the differential diagnosis of unclear thyrotoxicosis, 16, 17 especially in combination with medical history, typical clinical features and test parameters. 18 The current study assessed the correlation between STA-PSV and RAIU in Chinese patients with thyrotoxicosis. Mean STA-PSV for patients with Graves' disease was significantly higher than for patients with destructive thyroiditis, consistent with a study in Japanese patients. 19 STA-PSV correlated positively and significantly with RAIU findings in the current study. This correlation was similar if analysed separately for patients with Graves' disease and destructive thyroiditis (data not shown). Other studies have reported the effectiveness of thyroid blood flow 20 and PSV 18, 19, 21 in discriminating thyrotoxicosis, but do not show data for RAIU. To our knowledge, this study is the first to show the correlation between PSV and RAIU, and to provide a cutoff value for PSV.
Research has demonstrated that stimulation of the thyroid by TSH or TRAb resulted in increased thyroid blood flow. 22 In clinical practice, TSH preparation before isotope therapy for thyroid carcinoma may lead to thyroid follicle hyperplasia and increased thyroid blood flow. 23 The current study, however, failed to find any statistically The current study indicated that mean STA-PSV is clinically valuable in the aetiological exploration of thyrotoxicosis, especially in the differential diagnosis of Graves' disease and destructive thyroiditis, which is in agreement with other published findings. 19 In contrast, the FLT 3 /FLT 4 ratio was not useful in the differential diagnosis of these two diseases. PSV reflects the autonomous function of the thyroid 19 and may be suitable in circumstances when RAIU is contraindicated, such as in pregnancy and lactation, or in patients undergoing treatment involving iodine-containing drugs or contrast media.
The current study has several limitations. First, the data were collected both retrospectively and prospectively, which may have had an effect on study reliability. Secondly, the mechanism underlying the correlation between mean STA-PSV and RAIU is still to be explored. Thirdly, the association between RAIU and PSV is untested in the euthyroid population, since it is inappropriate to perform RAIU in people with normal thyroid function. Finally, this study did not include analysis of other types of thyrotoxicosis, such as thyrotoxicosis factitia caused by thyroxine overdose. Taking into account the correlation with RAIU, STA-PSV appears to be accurate, reliable and practical in the aetiological diagnosis of thyrotoxicosis. 
